• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项比较普通肝素与低分子量肝素片段的人体药理学研究。

A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment.

作者信息

Bratt G, Törnebohm E, Lockner D, Bergström K

出版信息

Thromb Haemost. 1985 Apr 22;53(2):208-11.

PMID:4024029
Abstract

The pharmacokinetics of a heparin fragment of low molecular weight (LMWH) of 4000-5000 D and unfractioned standard heparin (UFH) have been studied after i.v. injections of different doses and infusions in 8 humans. The heparin activity was significantly higher and the effect on APTT lower after LMWH fragment as compared to UFH in the same doses. The half-life of heparin activity was about 1 hr for UFH and about 2 hr for LMWH. LMWH was found to be eliminated according to first order kinetics and there were no signs of dose dependency.

摘要

对8名受试者静脉注射不同剂量并进行输注后,研究了分子量为4000 - 5000道尔顿的低分子量肝素(LMWH)片段和未分级标准肝素(UFH)的药代动力学。与相同剂量的UFH相比,LMWH片段的肝素活性显著更高,而对活化部分凝血活酶时间(APTT)的影响更低。UFH的肝素活性半衰期约为1小时,LMWH约为2小时。发现LMWH按一级动力学消除,且无剂量依赖性迹象。

相似文献

1
A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment.一项比较普通肝素与低分子量肝素片段的人体药理学研究。
Thromb Haemost. 1985 Apr 22;53(2):208-11.
2
Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.低分子量肝素(速碧林)与普通肝素对体内血栓形成部位凝血激活的影响。
Thromb Haemost. 1994 Dec;72(6):831-5.
3
Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.关于鱼精蛋白对人凝血系统激活部位的普通肝素和低分子量肝素(速避凝)的中和作用的研究。
Thromb Haemost. 1995 Mar;73(3):439-43.
4
A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis.低分子量肝素(KABI 2165)与标准肝素用于静脉治疗深静脉血栓形成的比较。
Thromb Haemost. 1985 Dec 17;54(4):813-7.
5
Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin--a three way cross over study in human volunteers.低分子量肝素(依诺肝素)皮下注射后的药代动力学和药效学,与普通肝素的比较——一项在人类志愿者中的三交叉研究
Thromb Haemost. 1994 Mar;71(3):305-13.
6
Pharmacokinetic and pharmacodynamic characterization of a medium-molecular-weight heparin in comparison with UFH and LMWH.与普通肝素和低分子肝素相比,中分子量肝素的药代动力学和药效学特征。
Semin Thromb Hemost. 2002 Aug;28(4):369-78. doi: 10.1055/s-2002-34306.
7
Plasma kinetics of lipoprotein lipase and hepatic lipase activities induced by heparin and a low molecular weight heparin fragment.
Scand J Clin Lab Invest. 1987 Apr;47(2):151-5.
8
Covalent complexes between low molecular weight heparin fragments and antithrombin III - inhibition kinetics and turnover parameters.
Thromb Haemost. 1983 Apr 28;49(2):109-15.
9
Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers.与传统肝素相比,酶解肝素对健康志愿者的影响。
Thromb Haemost. 1987 Feb 3;57(1):97-101.
10
Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential.由于凝血酶潜力降低,与成人血浆相比,抑制新生儿和儿童血浆中凝血酶生成所需的类肝素浓度降低。
Thromb Haemost. 2002 Apr;87(4):606-13.

引用本文的文献

1
Pitfalls in Argatroban Monitoring: Heparin Interference With Dilute Thrombin Time Assays.阿加曲班监测中的陷阱:肝素对稀释凝血酶时间测定的干扰。
Int J Lab Hematol. 2025 Oct;47(5):989-991. doi: 10.1111/ijlh.14505. Epub 2025 May 26.
2
Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease.达肝素:其在预防和治疗血栓栓塞性疾病方面的药理特性及临床疗效的最新进展
Drugs. 2000 Jul;60(1):203-37. doi: 10.2165/00003495-200060010-00010.
3
Pharmacokinetic optimisation of the treatment of deep vein thrombosis.
深静脉血栓形成治疗的药代动力学优化
Clin Pharmacokinet. 1997 Feb;32(2):145-72. doi: 10.2165/00003088-199732020-00005.
4
Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.达肝素钠。其药理学及在预防和治疗血栓栓塞性疾病中的临床应用综述。
Drugs. 1996 Aug;52(2):276-305. doi: 10.2165/00003495-199652020-00011.
5
Evidence of an absorption phase after short intravenous suramin infusions.短时间静脉注射苏拉明后吸收阶段的证据。
Cancer Chemother Pharmacol. 1993;31(6):495-9. doi: 10.1007/BF00685042.
6
A low molecular weight heparin in hemodialysis.血液透析中的低分子量肝素。
Klin Wochenschr. 1988 Mar 15;66(6):246-9. doi: 10.1007/BF01748164.
7
Investigations on plasma activity of low molecular weight heparin after intravenous and oral administrations.静脉注射和口服低分子量肝素后血浆活性的研究。
Br J Clin Pharmacol. 1989 Aug;28(2):188-92. doi: 10.1111/j.1365-2125.1989.tb05415.x.
8
A prospective randomized trial of low molecular weight heparin-DHE and conventional heparin-DHE (with acenocoumarol) in patients undergoing gynaecological surgery.低分子量肝素 - 二氢麦角胺与传统肝素 - 二氢麦角胺(联合醋硝香豆素)用于妇科手术患者的前瞻性随机试验。
Arch Gynecol Obstet. 1989;244(3):141-50. doi: 10.1007/BF00931291.
9
Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.剂量调整的肝素治疗深静脉血栓形成:普通肝素与低分子量肝素的比较
Eur J Clin Pharmacol. 1990;39(2):107-12. doi: 10.1007/BF00280041.
10
Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.普通肝素和低分子量肝素的药物治疗学方面
Drugs. 1990 Oct;40(4):498-530. doi: 10.2165/00003495-199040040-00003.